The term ‘quarantine myopia’ has been coined to describe what appears to be a worsening of the condition in many paediatric patients due to lockdowns across the world. RHIANNON BOWMAN asks whether Australian optometrists and parents should be worried. Read more
Device Technologies has introduced a new surgical laser system that allows cataract surgeons to perform highly accurate and consistent capsulotomies in less than one third of a second, ensuring precise size, circularity and position. Read more
Safilo has announced it will begin incorporating two new sustainable materials containing recycled content into its eyewear collections, beginning with its proprietary brand Polaroid. Read more
A leading ophthalmic lens supplier is urging eyecare professionals to educate patients about the importance of spectacle hygiene and anti-fog properties in the COVID-19 era, which are presenting new business opportunities for practices. Read more
Nova Eye Medical has announced positive five-year follow-up data from a sub-study analysis of the multi-centre LEAD trial for its 2RT nano-pulse ophthalmic laser therapy. Read more
Recently published results of an extensive study into the physiological response to daily disposable soft contact lenses are adding to a growing body of evidence in support of contact lens wear in children for myopia control. Read more
Transitions Optical is giving away 200 VISA gift cards valued at $50 each to eyecare professionals that register and complete education modules as part of its relaunch of the Transitions Plus portal. Read more
An Australian software solution that measures visual fields on multiple platforms, including iPad, has now been translated into a browser-based interface, making it compatible with common IT equipment. Read more
Device Technologies has introduced a new Topcon binocular refraction system to the Australian market, combining autorefraction, keratometry and subjective refraction in a single device. Read more
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a hepatitis C drug to become the costliest subsidised drug for the first time. Read more